Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 12, 2022 16:05 ET
|
Vincerx Pharma, Inc.
Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting Presented preliminary findings on VIP152 in gynecologic malignancies in poster at AACR Annual...
Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022
April 08, 2022 13:05 ET
|
Vincerx Pharma, Inc.
VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented for VIP152-treated patients with gynecologic...
Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
March 29, 2022 08:00 ET
|
Vincerx Pharma, Inc.
Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101 Preliminary findings in gynecologic malignancies will be presented as a poster at upcoming AACR Annual Meeting in...
Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 08, 2022 16:35 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
February 09, 2022 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers
February 03, 2022 08:30 ET
|
Vincerx Pharma, Inc.
VIP236 is a first-in-class anticancer agent, optimized using Vincerx’s proprietary modular bioconjugation platform to target aggressive tumors VIP236 demonstrates promising tumor regression in in...
Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
December 17, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting
December 11, 2021 15:30 ET
|
Vincerx Pharma, Inc.
VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx hosting KOL webinar today, Saturday, December...
Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma
December 07, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Hosting Key Opinion Leader Webinar on VIP152 Data Presented at the American Society of Hematology Annual Meeting
December 06, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...